Sandoz Agrees to $400 Million Settlement Over Generic Drug Price Fixing
Oregon Attorney General Dan Rayfield announced a $400 million settlement with generic drug manufacturer Sandoz over allegations that the company conspired to inflate prescription medication costs and suppress competition. The resolution, submitted to a federal judge for approval, addresses claims brought by Oregon and 42 other states and territories, and provides potential restitution for consumers who purchased specific generic drugs between May 2009 and December 2019.
Allegations of Price Fixing and Sandoz Settlement Terms
State investigators alleged that Sandoz worked alongside other competing pharmaceutical companies to drive up prices on dozens of common generic medications. The multi-state lawsuit claims that corporate executives used coded terms like “fair share” and “playing nice in the sandbox” to divide customers and coordinate price increases rather than competing in the open market. Under the terms of the proposed resolution, Sandoz will pay $400 million. Combined with prior settlements reached by the corporation, the total payout reaches approximately $469 million. The settlement also resolves claims directed at Sandoz’s current and former parent and sister companies overseas, including Novartis. Beyond financial penalties, the agreement mandates internal structural reforms to ensure future compliance with antitrust laws.
Oregon Consumers May Qualify for Settlement Compensation
Oregon’s share of the settlement totals approximately $4.76 million. Of that sum, $1.8 million is designated for damages, Medicaid reimbursements, and other agency recoveries, while an estimated $2.96 million is set aside for eligible Oregon consumers. Residents who purchased certain generic prescription drugs in the United States between May 2009 and December 2019 may qualify for financial compensation from the pool. In addition to Oregon, the participating jurisdictions include Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, the Northern Mariana Islands, Ohio, Oklahoma, Pennsylvania, Puerto Rico, Rhode Island, South Dakota, Tennessee, the U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
Evidence Gathered by State Investigators
State investigators built the antitrust case by reviewing more than 20 million documents and phone records spanning over 600 individuals within the generic drug industry. Evidence demonstrated that sales and pricing executives maintained regular contact through cocktail parties, industry dinners, golf outings, text messages, emails, and phone calls. A cooperating witness preserved a two-volume notebook detailing conversations held with competitors over a multi-year period. Previous settlements involving other generic drug manufacturers—including Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage parent company Emcure—total $96.5 million, alongside cooperating settlements from two former Heritage executives.
Upcoming February 2027 Trial Against Remaining Drug Companies
The resolution with Sandoz marks the latest development in a broader series of antitrust lawsuits initiated by nearly every state beginning in 2016 against more than 40 generic drug companies and dozens of corporate executives. Additional legal actions against remaining defendants in the price-gouging litigation remain active, with the first scheduled trial against other participating drug makers set to begin in February 2027.